A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials

J Urol. 2005 Nov;174(5):1759-63; discussion 1763. doi: 10.1097/01.ju.0000177487.64651.3a.

Abstract

Purpose: We developed a clinically useful scoring algorithm to predict cancer specific survival for patients with clear cell metastatic renal cell carcinoma (RCC).

Materials and methods: We studied 727 patients treated with radical nephrectomy for clear cell RCC from 1970 to 2000 who had distant metastases at nephrectomy (285) or in whom metastases subsequently developed (442). A scoring algorithm to predict cancer specific survival was developed using the regression coefficients from a Cox proportional hazards model.

Results: There were 606 deaths from clear cell RCC at a median of 1.0 years (range 0 to 14) following metastatic RCC. Constitutional symptoms at nephrectomy (+2), metastases to the bone (+2) or liver (+4), metastases in multiple simultaneous sites (+2), metastases at nephrectomy (+1) or within 2 years of nephrectomy (+3), complete resection of all metastatic sites (-5), tumor thrombus level I to IV (+3), and the primary pathological features of nuclear grade 4 (+3) and histological tumor necrosis (+2) were significantly associated with death from RCC. All patients started with a score of 0 and points were added or subtracted as indicated in parentheses. Cancer specific survival rates at 1 year were 85.1%, 72.1%, 58.8%, 39.0%, and 25.1%, respectively, for patients with scores of -5 to -1, scores of 0 to 2, scores of 3 to 6, scores of 7 or 8, and scores of 9 or more.

Conclusions: This scoring algorithm can be used to predict cancer specific survival for patients with metastatic clear cell RCC.

Publication types

  • Comparative Study

MeSH terms

  • Adenocarcinoma, Clear Cell / mortality*
  • Adenocarcinoma, Clear Cell / secondary
  • Adenocarcinoma, Clear Cell / surgery
  • Adult
  • Age Distribution
  • Aged
  • Algorithms*
  • Carcinoma, Renal Cell / mortality*
  • Carcinoma, Renal Cell / secondary
  • Carcinoma, Renal Cell / surgery
  • Cause of Death*
  • Clinical Trials as Topic
  • Female
  • Humans
  • Incidence
  • Kidney Neoplasms / mortality*
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / surgery
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Nephrectomy / methods
  • Predictive Value of Tests
  • Probability
  • Prognosis
  • Prospective Studies
  • Registries
  • Retrospective Studies
  • Risk Assessment
  • Sex Distribution
  • Survival Analysis